Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 3Tumor-Agnostic 1

Conditions

Fallopian Tube Neoplasms 14Ovarian Neoplasms 12Carcinoma, Ovarian Epithelial 8Neoplasms 4Triple Negative Breast Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 2Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Neoplasms × mirvetuximab soravtansine × Clear all
NCT05445778 2026-06-02

GLORIOSA

AbbVie

Phase 3 Active not recruiting
520 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05041257 2026-01-09

PICCOLO

AbbVie

Phase 2 Completed
79 enrolled 14 charts
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05456685 2025-10-28

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

AbbVie

Phase 2 Active not recruiting
125 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT01609556 2021-02-17

IMGN853-0401

ImmunoGen, Inc.

Phase 1 Completed
206 enrolled 46 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡